Biosimilars: Pipeline Trends available on ReportsnReports

Biosimilars: Pipeline Trends 

Biosimilar and copy-biologic markets are dominated by versions of simple biologic molecules. However, there is an increasing trend towards the development of high value biologics such as monoclonal antibodies (MAbs), with rituximab currently the most targeted molecule, with 14 pipeline biosimilar candidates in development.

The EU leads in terms of the number of marketed and pipeline biosimilar candidates followed by South Korea, while India continues to lead the way in the copy-biologics market, followed by China.

Based on company reported information, Sandoz was highlighted as the leading company in terms of marketed and pipeline biosimilars, while Zydus Cadilla leads in terms of copy-biologic development.

 Request a Sample for or Inquire before buying the report

http://www.reportsnreports.com/reports/143563-biosimilars-pipeline-trends.html

Features and benefits

• Compares key molecules targeted by biosimilar and copy-biologic developers.
• Insight into leading therapy areas and indications targeted by biosimilar and copy-biologic developers.
• Assess the key geographies targeted by biosimilar and copy-biologic developers.
• Analyses the portfolios of key biosimilar and copy-biologic developers.

Major points covered in Table of Contents of this report include

Introduction
Strategic scoping and focus
Related reports
Key findings
Biosimilars/copy-biologics metrics
Leading countries in terms of pipeline and marketed biosimilars and copy-biologics
Biosimilars by molecule type
Copy-biologics by molecule type

Explore Comprehensive list of more than 79 Tables & Figures available in the report Biosimilars: Pipeline Trends 

Report Details:
Published: December 2011
No. of Pages:
Price: Single User License – US$2400     Corporate User License-